Free tool
Drug Trial Radar: Neurology
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
1,034
Completed, industry sponsors, Neurology, Phase 3
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting104
- Completed1,034
1,034 trials
Showing 1 to 25, recently updated first.
- A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut SyndromePivotal-lookingCompleted
Zogenix, Inc.Industry
NCT03936777 · 412 participants · Start Apr 22, 2019 · Primary completion May 8, 2025
Drug: ZX008 (Fenfluramine Hydrochloride) · For: Dravet Syndrome; Lennox Gastaut Syndrome; Epileptic Encephalopathy
Sites: Tucson, Arizona; Los Angeles, California; San Diego, California · 71 sites in all
- Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT03615326 · 738 participants · Start Oct 5, 2018 · Primary completion Mar 20, 2024
Drug: Pembrolizumab; Placebo and 6 more · For: Gastric Neoplasms; Gastroesophageal Junction Adenocarcinoma
Sites: Los Angeles, California; Monterey, California; Orange, California · 192 sites in all
- Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT02504372 · 1,177 participants · Start Nov 6, 2015 · Primary completion Jan 24, 2023
Drug: Pembrolizumab · For: Non-small Cell Lung Cancer
- A Study to Evaluate the Efficacy and Safety of HRG2010 in Parkinson's Disease With Motor FluctuationsPivotal-lookingCompleted
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT06596876 · 165 participants · Start Nov 6, 2024 · Primary completion Jan 29, 2026
Drug: HRG2010; Sustained-release Carbidopa/Levodopa administered placebo; Sustained-release Carbidopa/Levodopa; HRG2010 placebo · For: Parkinson's Disease
Sites: Beijing, China
- Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to HistopathologyPivotal-lookingCompleted
Lantheus Biosciences Ltd.Industry
NCT01020838 · 218 participants · Start Nov 2009 · Primary completion Sep 2011
Drug: Florbetaben (BAY94-9172) · For: Alzheimer Disease
Sites: Sun City, Arizona; Stanford, California; Tampa, Florida · 19 sites in all
- Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04221945 · 1,060 participants · Start May 12, 2020 · Primary completion Jan 7, 2025
Drug: Pembrolizumab; Placebo for pembrolizumab and 1 more · For: Uterine Cervical Neoplasms
Sites: Phoenix, Arizona; Los Angeles, California; Newport Beach, California · 176 sites in all
- SkinTE® for the Treatment of Wagner 1 Diabetic Foot Ulcers (COVER DFUS II)Pivotal-lookingCompleted
PolarityTEIndustry
NCT06140303 · 120 participants · Start Feb 22, 2024 · Primary completion Jan 30, 2026
Drug: SkinTE · For: Diabetic Foot
Sites: Mesa, Arizona; Castro Valley, California; Fresno, California · 23 sites in all
- Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04210115 · 703 participants · Start Feb 28, 2020 · Primary completion Jan 21, 2026
Drug: pembrolizumab; placebo and 5 more · For: Esophageal Squamous Cell Carcinoma (ESCC); Gastroesophageal Junction Carcinoma (GEJC); Esophageal Adenocarcinoma (EAC)
Sites: Long Beach, California; Columbus, Georgia; Westwood, Kansas · 170 sites in all
- A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence EpilepsyPivotal-lookingCompleted
NCT04666610 · 154 participants · Start Jul 29, 2021 · Primary completion Jul 7, 2026
Drug: Brivaracetam · For: Childhood Absence Epilepsy; Juvenile Absence Epilepsy
Sites: Birmingham, Alabama; Orange, California; Denver, Colorado · 35 sites in all
- Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic MigrainePivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT03832998 · 284 participants · Start Sep 5, 2019 · Primary completion Jan 8, 2025
Drug: Erenumab Dose 1; Erenumab Dose 2 and 1 more · For: Migraine
Sites: San Diego, California; Aurora, Colorado; Colorado Springs, Colorado · 101 sites in all
- A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia GravisPivotal-lookingCompleted
NCT06149559 · 14 participants · Start Jun 14, 2024 · Primary completion Oct 5, 2026
Drug: rozanolixizumab · For: Generalized Myasthenia Gravis
Sites: Bologna, Italy; Milan, Italy; Naples, Italy · 9 sites in all
- Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL AmyloidosisPivotal-lookingCompleted
Lantheus Germany GmbHIndustry
NCT05184088 · 244 participants · Start Jan 13, 2023 · Primary completion Apr 21, 2026
Drug: [18F]florbetaben · For: Cardiac Amyloidosis; AL Amyloidosis; ATTR Amyloidosis
Sites: Kansas City, Kansas; Philadelphia, Pennsylvania; Pittsburgh, Pennsylvania · 14 sites in all
- Efficacy and Safety of Rizatriptan-Naproxen (10/550 mg) in the Acute Treatment of MigrainePivotal-lookingCompleted
Eurofarma Laboratorios S.A.Industry
NCT04384367 · 2,068 participants · Start Dec 30, 2022 · Primary completion Oct 30, 2024
Drug: Rizatriptan 10 mg + Naproxen 550mg; Maxalt 10Mg Tablet and 2 more · For: Migraine
Sites: São Paulo, Brazil · 2 sites in all
- Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) SeizuresPivotal-lookingCompleted
SK Life Science, Inc.Industry
NCT05067634 · 154 participants · Start Jan 10, 2022 · Primary completion Oct 2, 2026
Drug: Xcopri · For: Partial Epilepsy
Sites: Phoenix, Arizona; Palo Alto, California; Hartford, Connecticut · 35 sites in all
- Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia GravisPivotal-lookingCompleted
NCT04225871 · 200 participants · Start Dec 23, 2019 · Primary completion Jul 31, 2026
Drug: zilucoplan (RA101495) · For: Generalized Myasthenia Gravis
Sites: Mobile, Alabama; Phoenix, Arizona; Irvine, California · 70 sites in all
- Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT03924856 · 907 participants · Start Jun 13, 2019 · Primary completion Jan 26, 2026
Drug: Pembrolizumab; Gemcitabine and 2 more · For: Bladder Cancer
Sites: La Jolla, California; Santa Monica, California; Washington D.C., District of Columbia · 175 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04956692 · 531 participants · Start Aug 5, 2021 · Primary completion Apr 4, 2023
Drug: Pembrolizumab SC; Pembrolizumab IV and 5 more · For: Non-Small Cell Lung Cancer
Sites: Jonesboro, Arkansas; Fullerton, California; Los Alamitos, California · 126 sites in all
- An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD SubjectsPivotal-lookingCompleted
Alzheon Inc.Industry
NCT04770220 · 325 participants · Start May 19, 2021 · Primary completion May 29, 2024
Drug: Experimental: ALZ-801; Placebo Comparator: Placebo · For: Early Alzheimer's Disease
Sites: Phoenix, Arizona; Scottsdale, Arizona; Sun City, Arizona · 95 sites in all
- Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)Pivotal-lookingCompleted
Incyte CorporationIncyte (INCY)
NCT03358472 · 89 participants · Start Dec 1, 2017 · Primary completion Jul 19, 2018
Drug: Pembrolizumab; Epacadostat and 4 more · For: Head and Neck Cancer
Sites: Anaheim, California; Sacramento, California; Santa Rosa, California · 73 sites in all
- Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT03976323 · 1,003 participants · Start Jun 28, 2019 · Primary completion Feb 7, 2024
Drug: Pembrolizumab; Pemetrexed and 3 more · For: Carcinoma, Nonsquamous Non-small-cell Lung
Sites: Birmingham, Alabama; Muscle Shoals, Alabama; Burbank, California · 178 sites in all
- This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)Pivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03599245 · 1,055 participants · Start Jul 12, 2018 · Primary completion Jul 17, 2025
Drug: Ocrelizumab · For: Multiple Sclerosis
Sites: Buenos Aires, Argentina; Ciudad Autonoma Buenos Aires, Argentina; Rosario, Argentina · 161 sites in all
- A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet SyndromePivotal-lookingCompleted
NCT06118255 · 25 participants · Start May 21, 2024 · Primary completion Sep 1, 2026
Drug: fenfluramine · For: Dravet Syndrome
Sites: Memphis, Tennessee; Dallas, Texas; Seattle, Washington · 12 sites in all
- Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With MigrainePivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT06241313 · 2,158 participants · Start Mar 25, 2024 · Primary completion Jul 7, 2025
Drug: Atogepant; Placebo for Atogepant · For: Migraine
Sites: Edegem, Belgium; Jette, Belgium; Saint-Nicolas, Belgium · 149 sites in all
- A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut SyndromePivotal-lookingCompleted
TakedaTakeda (TAK)
NCT04938427 · 270 participants · Start Nov 8, 2021 · Primary completion Jan 25, 2024
Drug: Placebo; Soticlestat · For: Lennox Gastaut Syndrome (LGS)
Sites: Phoenix, Arizona; Tucson, Arizona; Los Angeles, California · 98 sites in all
- A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet SyndromePivotal-lookingCompleted
TakedaTakeda (TAK)
NCT04940624 · 144 participants · Start Oct 28, 2021 · Primary completion Apr 11, 2024
Drug: Soticlestat; Placebo · For: Dravet Syndrome (DS)
Sites: Phoenix, Arizona; Los Angeles, California; San Francisco, California · 66 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.